The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.
In this series, David takes a look at three health-care stocks that have doubled and examines whether they can keep it going for the rest of the year. Today's edition features Omeros, with its PharmacoSurgery program, Amylin, which has apparently no shortage of Big Pharma suitors, and Regeneron, after its successful launch of Eylea. Can these stocks keep running? Watch and find out.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
David Williamson and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.